Novartis Stock

Novartis Forward P/E

The Forward P/E Ratio of Novartis (NOVN.SW) as of Aug 12, 2026 is 25.96. In the previous year, Forward P/E Ratio was 31.84 — a change of -18.49% (lower).

Forward P/E

25.96

YoY

-18.49%

Last updated:

Forward P/E Ratio of Novartis is 2026 25.96 . Forward P/E Ratio of Novartis was 2025 31.84 . It decreases by -18.49% lower compared to the previous year.
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

Forward P/E Ratio of Novartis is 25.96 in 2026.

Forward P/E Ratio of Novartis changed from 31.84 to 25.96, representing a -18.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Novartis since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Novartis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Novartis

All Key Metrics — Novartis